Brief: Daiichi Sankyo To Spend Roughly 300 Billion Yen To Set Up Production Facilities For Targeted Cancer Medicine, Nikkei Reports
Health Rounds: Language in health research grants is changing under political pressure
UK Stocks-Factors to watch on December 16 (updated)
Live Markets: Before the bell: Europe tracks lower, led by defence
Brief: FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With Pertuzumab
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment (updated)
US FDA approves Daiichi Sankyo's therapy to treat breast cancer
Brief: Federal Circuit Court Of Appeals Vacates Infringement Judgment And Damages Award In Dispute Between Daiichi Sankyo And Seagen
Federal Circuit Court Of Appeals Vacates Infringement Judgment And Damages Award In Dispute Between Daiichi Sankyo And Seagen
Daiichi wins appeal of $42 million US verdict in Enhertu patent case (updated)
Daiichi wins appeal of $42 million US verdict in Enhertu patent case
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Brief: General Proximity, Daiichi Sankyo Partner to Advance Novel Oncology Therapeutics Using OmniTAC
Brief: DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Table: Daiichi Sankyo 6-MTH group results (IFRS)
Brief: Daiichi Sankyo To Invest Around 90 Billion Yen In Japan For Next Generation Pharmaceutical Research And Development, Nikkei Says
Japan's Nikkei crosses 51,000 for first time on tech optimism (updated)
Japan's Nikkei hits record high as AI optimism lifts investor sentiment